New hope for tough esophageal cancer: SYS6010 trial launches
NCT ID NCT07417735
First seen Feb 22, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This study tests a new drug called SYS6010 against standard chemotherapy for people with advanced esophageal cancer that has worsened after at least one prior treatment. About 436 participants will be randomly assigned to receive either SYS6010 or a standard chemo drug chosen by their doctor. The main goals are to see if SYS6010 helps people live longer without their cancer growing and improves overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC/RECURRENT ESCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.